Role of ASA in the primary and secondary prevention of cardiovascular events

• Published in: Baillière's best practice & research. Clinical gastroenterology Vol. 26; no. 2; pp. 113 - 123
• Main Authors: Casado-Arroyo, Rubén, MD, Bayrak, Fatih, MD, Sarkozy, Andrea, MD, PhD, Chierchia, Gian-Battista, MD, Asmundis, Carlo de, MD, PhD, Brugada, Pedro, MD, PhD
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01-04-2012; Elsevier Limited
• Subjects: Aspirin; Aspirin - adverse effects; Aspirin - therapeutic use; Cardiovascular disease; Cardiovascular Diseases - prevention & control; Gastroenterology and Hepatology; Heart attacks; Humans; Mortality; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - therapeutic use; Primary Prevention; Secondary Prevention; Sex Factors; Womens health; United States > US; Secondary prevention; Cardiovascular disease; Aspirin; Primary prevention
• ISSN: 1521-6918; 1532-1916
• DOI: 10.1016/j.bpg.2012.01.013

Cardiovascular disease, which includes coronary heart disease, cerebrovascular disease and peripheral artery disease, is the leading cause of death in developed countries. Evidence from basic research, clinical investigations, observational epidemiologic studies and randomized clinical trials has provided strong support for the benefits of aspirin in decreasing the risk of cardiovascular events in a wide range of pathologies in secondary prevention. Data in primary prevention have far more uncertainties. An overview for the evidence supporting the efficacy of aspirin in primary and secondary prevention of cardiovascular disease is discussed, including the relative and absolute benefit and the risks of side effects. Finally, future developments in the field directed towards individualized treatment strategies and novel antiplatelet agents are examined.